The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells

The cytosolic 5'-nucleotidase cN-II is a highly conserved enzyme implicated in nucleotide metabolism. Based on recent observations suggesting additional roles not directly associated to its enzymatic activity, we studied human cancer cell models with basal or decreased cN-II expression. We deve...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 8; no. 40; pp. 67380 - 67393
Main Authors Bricard, Gabriel, Cadassou, Octavia, Cassagnes, Laure-Estelle, Cros-Perrial, Emeline, Payen-Gay, Léa, Puy, Jean-Yves, Lefebvre-Tournier, Isabelle, Tozzi, Maria Grazia, Dumontet, Charles, Jordheim, Lars Petter
Format Journal Article
LanguageEnglish
Published United States Impact journals 15.09.2017
Impact Journals LLC
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The cytosolic 5'-nucleotidase cN-II is a highly conserved enzyme implicated in nucleotide metabolism. Based on recent observations suggesting additional roles not directly associated to its enzymatic activity, we studied human cancer cell models with basal or decreased cN-II expression. We developed cancer cells with stable inhibition of cN-II expression by transfection of shRNA-coding plasmids, and studied their biology. We show that human breast cancer cells MDA-MB-231 with decreased cN-II expression better adapt to the disappearance of glucose in growth medium under normoxic conditions than cells with a baseline expression level. This is associated with enhanced growth and a lower content of ROS in cells cultivated in absence of glucose due to more efficient mechanisms of elimination of ROS. Conversely, cells with low cN-II expression are more sensitive to glucose deprivation in hypoxic conditions. Overall, our results show that cN-II regulates the cellular response to glucose deprivation through a mechanism related to ROS metabolism and defence.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.18653